AZZALURE®

About Azzalure® — Galderma’s European Aesthetic Botulinum Toxin

Azzalure® is a botulinum toxin type A aesthetic formulation of abobotulinumtoxinA. Ipsen manufactures the active substance; Galderma holds the aesthetic marketing rights across the EU and UK, which is why the product carries the Galderma name in clinical settings even though the underlying biologic is Ipsen’s. [4]

What Azzalure® actually does at the neuromuscular junction is the same across the class: it interrupts the release of acetylcholine from presynaptic nerve terminals, and the muscle fibers it targets cannot fully contract until new active protein is produced. As a muscle relaxant, its aesthetic value comes from that temporary reduction in contraction, which softens the surface expression of dynamic wrinkles without eliminating movement in adjacent, untreated areas. [1][4]

• It is CE-marked for aesthetic use in the European Economic Area and the United Kingdom [4].
• The single approved presentation is a 125U lyophilized powder that must be reconstituted before injection [4].
• Its licensed indications are moderate to severe glabellar lines and lateral canthal lines (crow’s feet) in adults under 65 [4].
• The active substance is identical to what is sold globally as DYSPORT®, though the branding, licensing, and indication scope differ.

Is Azzalure® the Same as DYSPORT®? The Brand vs Market Distinction

The two botulinum toxins are not the same: Azzalure® and DYSPORT® are both abobotulinumtoxinA from Galderma and Ipsen. What separates them is jurisdiction and indication scope, not the molecule in the vial. [4]

DYSPORT® holds FDA approval in the United States and is licensed across a wider range of aesthetic and therapeutic indications depending on the market. Azzalure® is confined to the EU and UK and is licensed for aesthetic use only, currently covering moderate to severe glabellar lines seen at maximum frown and lateral canthal lines seen at maximum smile [4]. Because both products run on the Speywood, or Galderma, unit, a practitioner moving a patient between Azzalure® and DYSPORT® for a comparable treatment does not need to recalculate the dose.

Galderma units are not equivalent to BOTOX® units. Published guidance commonly puts the conversion at roughly 2.5 to 3 Galderma units for every 1 BOTOX® unit in glabellar treatment, and the ratio remains an active point of discussion in the peer-reviewed literature [2]. Treating that number as an approximation, not a fixed conversion, is the safer clinical posture.

Azzalure® 125U — Vial Presentation and Pack Format

Azzalure® is only available in one strength: a single 125 Speywood unit vial of lyophilized powder, packaged as an Azzalure 125IU 2 vials pack [4]. Unlike some competitors that offer multiple unit counts within the same brand, Azzalure® offers only this presentation. That simplifies ordering, but it also means dosing planning must be based on a fixed vial size. Use each reconstituted vial for one patient in a single session.

How to Reconstitute Azzalure® — Dilution and Preparation

Reconstitution is the step where dosing accuracy is either set up or lost. For Azzalure®, the labeled approach uses sterile 0.9% sodium chloride, and the concentration follows the volume chosen [4]:

• Standard dilution: add 1.25 mL of saline to the 125U vial to yield 10 U per 0.1 mL.
• Alternative dilution: add 2.5 mL of saline for a lower concentration of 5 U per 0.1 mL, which some clinicians prefer when spreading the dose across a broader area.

After adding saline, rotate the vial slowly to mix. Do not shake. Vigorous agitation can damage the toxin’s protein structure and reduce potency. The finished solution should be clear and colorless; discard anything cloudy, discolored, or containing visible particulate.

Inject Azzalure® into the skin overlying the target muscle in small, measured aliquots. For glabellar treatment, distribute the labeled dose across the corrugator and procerus muscles, with careful attention to the orbital rim to reduce the risk of eyelid ptosis. Injection technique should always follow the current SmPC and IFU for the specific market presentation, since intramuscular depth, spacing, and volume all interact with the dilution chosen at reconstitution.

Use the reconstituted product within 24 hours and keep it refrigerated during that time. Unopened vials may be unrefrigerated under defined SmPC conditions rather than any extended room-temperature storage.

Treatment Areas and Clinical Indications

Azzalure®’s licensed indications are narrowly limited to aesthetic use: temporary improvement of moderate to severe glabellar lines seen at maximum frown, and moderate to severe lateral canthal lines seen at maximum smile, in adults under 65 when the severity of the lines has an important psychological impact [4]. Lateral canthal lines were added to the EU/UK authorization in 2018 and now sit alongside the original glabellar indication. Dynamic wrinkles are often caused by repeated contraction of the underlying facial muscles, and by reducing that activity, Azzalure® can reduce the appearance of wrinkles at the treated site while movement is retained elsewhere on the face.

Off-label, practitioners may extend the product to areas with an established evidence base. Common uses include:

• Forehead wrinkles across the frontalis
• Eyebrow shaping and lip refinement, including the lip flip
• Platysmal bands in the neck
• Selected skin depressions where treatment goals are conservative

Severe underarm sweating is a different situation. Botulinum toxin type A is used for hyperhidrosis in several markets, but that indication in this manufacturer’s portfolio is more commonly associated with DYSPORT® than with Azzalure® specifically. Whether Azzalure® covers hyperhidrosis under a given country’s authorization must be confirmed against local labeling before treatment.

Onset, Duration, and Clinical Performance

Onset is typically visible within 2 to 5 days of injection, with the full result developing over roughly 10 to 14 days [1]. Some clinicians report that Azzalure® treatments work slightly sooner than other botulinum toxin type A products in day-to-day practice, though randomized comparison trials have not consistently shown a meaningful difference on this point [3]. Treating the observation as a plausible tendency rather than a proven advantage is the fair reading of the evidence.

Most patients see the effect persist for 3 to 4 months, and some retain a partial response at 5 or even 6 months, depending on dose, treated muscle mass, individual metabolism, and prior treatment history [1][4]. Whether Azzalure® is a good BOTOX® alternative depends on the practice’s priorities. For clinics whose caseload is weighted toward glabellar and lateral canthal work in the CE-marked indications, the clinical record is consistent, and the product’s behavior across repeated sessions is well characterized. For therapeutic indications, BOTOX® or DYSPORT® remain the more direct routes given their broader authorization sets.

Regulatory Status

Azzalure® is a CE-marked prescription-only medicine authorized for aesthetic use in the European Union and the United Kingdom. Its current scope of approval covers moderate to severe glabellar lines and lateral canthal lines in adults under 65, following the addition of the lateral canthal indication to the EU/UK label in 2018 [4]. It does not have FDA approval. In the United States, the same abobotulinumtoxinA molecule is licensed and sold as DYSPORT® by Galderma and Ipsen, which is the FDA-approved equivalent.

Prescription-only status is not a formality. It shapes how the product legally moves, who is permitted to receive it, and what documentation a supplier must produce. Doctor Medica works with licensed practitioners and can share information on the credentialing and regional-compliance side of the process when practitioners are evaluating a source.

Storage and Cold-Chain Requirements

Azzalure® is a temperature-sensitive biologic, and cold chain is not optional [4]:

• Unopened vials: store refrigerated at 2°C to 8°C. The current SmPC permits a single excursion to a temperature not exceeding 25°C for up to 72 hours within the shelf life. This is a one-off allowance for a single interruption of the cold chain, not a permission for routine room-temperature storage.
• Reconstituted product: refrigerate and use within 24 hours. The 24-hour figure is the microbiological ceiling, not a target.

Because temperature control matters this much, verify shipping conditions on arrival. Packaging integrity, cold-chain records where available, and vial appearance all merit a check before booking stock. Anyone considering how to buy Azzalure® wholesale should treat shipping as part of the product’s clinical profile, not a logistical afterthought.

Azzalure® Price and Cost-Per-Treatment Considerations

Azzalure® is positioned in the mid-to-premium band of the botulinum toxin type A market, in line with the broader Galderma portfolio. Any meaningful cost comparison against other BTX-A brands must account for unit potency rather than vial price alone. A vial of Azzalure® and a vial of BOTOX® carry different unit systems, and the 2.5–3 Galderma unit to 1 BOTOX® unit conversion changes what a headline per-vial figure actually buys per treatment [2].

Order volume, pack configuration, market authorization, shipping requirements, and jurisdictional taxes all affect the final quotation. Practitioners running the numbers to buy Azzalure® wholesale usually find the per-treatment economics compare favorably when treatment volume for the authorized glabellar and lateral canthal indications is high, and less so when the practice leans heavily on off-label areas better served by products with a wider indication footprint. Licensed practitioners looking to order Azzalure® wholesale or order Azzalure® online can contact Doctor Medica representatives for guidance on current pricing structures and account eligibility.

Comparison of Azzalure® to Other Botulinum Toxin Type A Products

Azzalure® vs DYSPORT®

Same molecule, same manufacturer, different market. DYSPORT® is the FDA-approved abobotulinumtoxinA product with a broader indication set spanning aesthetic and therapeutic uses. Azzalure® is the EU/UK aesthetic-only expression of the same active substance, licensed for moderate to severe glabellar lines and lateral canthal lines [4]. Both use Speywood units, so a 125U vial of one is broadly equivalent to a 125U vial of the other for a comparable indication. Because Galderma units are not equivalent to BOTOX® units, the ~2.5–3:1 recalculation matters only when comparing either product to onabotulinumtoxinA [2].

Azzalure® vs BOTOX®

The clinically significant point in an Azzalure® vs BOTOX® comparison is unit interchangeability, or the absence of it. Azzalure® contains abobotulinumtoxinA and runs on Speywood units. BOTOX®, from AbbVie, contains onabotulinumtoxinA and uses its own unit system. Published consensus commonly cites 2.5 to 3 Speywood units per BOTOX® unit for glabellar treatment, though no single conversion has been endorsed as universal, and prescribing information for either product does not adopt one [2].

Regulatory reach is another split: BOTOX® holds FDA approval and CE marking across a much broader set of aesthetic and therapeutic indications, while Azzalure® is restricted to EU/UK aesthetic use. On onset, some clinical reports place Azzalure® at 2 to 5 days and BOTOX® at 3 to 7 days, but that gap is not consistently reproduced in head-to-head data [1]. BOTOX® carries the longest published clinical record of any product in the class, which for some clinics is the deciding factor even without a numerical advantage.

Azzalure® vs BOCOUTURE®

Both are CE-marked for aesthetic use in the EU and UK, and both are approved for glabellar lines. Beyond that, the formulations diverge. BOCOUTURE® contains incobotulinumtoxinA and is manufactured by Merz without accessory complexing proteins, which is where the informal “naked toxin” description comes from. The theoretical suggestion is that a formulation lacking complexing proteins may carry a lower immunogenicity risk over long-term repeated use, but the clinical significance of that theoretical difference remains uncertain in published data.

BOCOUTURE® is presented as 1:1 with BOTOX® units, so its unit system does not translate to Azzalure®’s Speywood system without conversion [2]. Storage is another practical difference. BOCOUTURE® can be kept at room temperature within labeled conditions, whereas Azzalure® requires refrigeration throughout. Both remain prescription-only.

Azzalure® vs XEOMIN®

XEOMIN® is the international, FDA-approved incobotulinumtoxinA brand marketed by Merz, and is essentially the international-facing sibling of BOCOUTURE®. Against Azzalure®, the differences are in the complexing protein profile, unit system, and storage. XEOMIN® units are treated as 1:1 with BOTOX® units. Azzalure® stays on Galderma units. XEOMIN® tolerates room-temperature storage, which is a logistical advantage some clinics weigh against Azzalure®’s cold-chain requirement [2].

No randomized head-to-head trial has directly compared Azzalure® and XEOMIN® for efficacy on a matched dose. Any Azzalure® vs other botulinum comparison at this level therefore relies on indirect data from separate studies, which limits how confidently a numerical difference in outcome can be attributed to the molecule itself.

Azzalure® vs NABOTA®

Different active substances, different manufacturers, different regulatory histories. NABOTA® contains prabotulinumtoxinA, produced by Daewoong Pharmaceutical in South Korea. It received FDA approval in 2019 as Jeuveau®, marketed by Evolus, for glabellar lines. Azzalure® remains without FDA approval but carries a longer EU/UK clinical track record. On dosing, NABOTA® is broadly positioned at 1:1 with BOTOX® units, while Azzalure® stays on Speywood units at the familiar ~2.5–3:1 ratio to BOTOX®. Both require refrigeration, and both hold approvals in overlapping European markets.

Clinical Benefits of Azzalure®

The case for Azzalure® in an established aesthetic practice sits on a few defined points:

• A single 125 Speywood unit vial size that simplifies stock control.
• A two-vial pack format that lends itself to bilateral treatment or multi-area sessions within one appointment.
• Onset is commonly reported at 2 to 5 days and duration in the 3 to 4 month range, with some patients extending beyond that [1].
• CE-marked authorization covering both glabellar and lateral canthal lines, which brings the two most commonly treated upper-face areas inside the licensed indication rather than off-label use.
• A diffusion profile characteristic of abobotulinumtoxinA formulations, which for broader upper-face treatment sites such as the forehead can be an advantage when the goal is even coverage across fine lines and wrinkles [3].

Some practitioners choose the two-vial format because it may align with how their appointments run. Rather than reconstituting a single vial per patient, the two-vial pack supports their session flow.

Side Effects and Safety

The commonly reported adverse reactions with Azzalure® are mild and short-lived [1]:

• Bruising at the injection site
• Headache
• Localized swelling
• Injection-site discomfort
• Transient asymmetry

The clinically more important events to watch for center on the upper face. Ptosis (eyelid drooping) is the most commonly reported significant adverse event for BTX-A treatments in the upper face generally, and Azzalure® is not exempt from that pattern [3]. Brow asymmetry can occur when dose or placement is not well calibrated. Side effects may include transient skin depressions at the injection site in some cases, generally related to technique rather than the formulation.

Rarely, distant spread of the toxin beyond the treatment site has been reported. This is a class-wide risk that applies to all BTX-A products, not something distinctive to Azzalure®. Contraindications include known hypersensitivity to botulinum toxin type A or any excipient, certain neuromuscular disorders, active infection at the intended injection site, and pregnancy, in line with the approved product information [4].

Finding Sourcing Information to Buy Azzalure® Online

Azzalure® is a prescription-only medicine and moves through authorized distribution channels to licensed practitioners rather than open-market retail [4]. What separates a reliable source from an unreliable one comes down to a handful of specifics that practitioners can verify before accepting delivery: cold-chain compliance documented across the shipping route, LOT number traceability, a certificate of analysis or authenticity aligned to the batch, and supplier credentials that stand up to scrutiny.

Are you looking to buy Azzalure®? Contact Doctor Medica representatives for guidance on availability and pricing. For those researching how to buy Azzalure® products or purchase Azzalure® for an authorized clinic, Doctor Medica’s staff can share information on account eligibility, sourcing documentation, and shipping requirements relevant to the practitioner’s jurisdiction.

Frequently Asked Questions

What is Azzalure®?

Azzalure® is a prescription abobotulinumtoxinA injectable produced by Ipsen and marketed by Galderma for aesthetic use in the EU and UK. It is CE-marked, supplied as a 125 Speywood unit lyophilized powder in a two-vial pack, and authorized for the treatment of moderate to severe glabellar lines and lateral canthal lines in adults under 65 [4].

What is Azzalure® used for?

The licensed indications are moderate to severe glabellar lines at maximum frown and moderate to severe lateral canthal lines at maximum smile in adults under 65 [4]. Off-label, clinicians extend it to forehead lines, eyebrow shaping, lip refinement, neck bands, and select skin depressions. Hyperhidrosis is more commonly associated with DYSPORT® in this manufacturer’s portfolio and should be confirmed against local labeling if being considered under the Azzalure® brand [3].

Is Azzalure® the same as DYSPORT®?

The active substance and manufacturer are identical. What differs is licensing: DYSPORT® is FDA-approved and marketed globally across a broader set of aesthetic and therapeutic indications, while Azzalure® is the EU/UK aesthetic-only expression of the same molecule, currently licensed for moderate to severe glabellar and lateral canthal lines [4].

How long does Azzalure® take to work?

Onset is typically noticeable within 2 to 5 days, with the full effect developing over 10 to 14 days [1]. Reports of a slightly faster onset than other BTX-A products are common but not consistently established in randomized comparison trials.

How long does Azzalure® last?

Duration in most patients is 3 to 4 months, with some retaining a partial response at 5 to 6 months depending on dose, muscle mass, metabolism, and treatment history [1][4].

How is Azzalure® reconstituted?

Add 1.25 mL of sterile 0.9% sodium chloride to the 125U vial for a concentration of 10 U per 0.1 mL, or 2.5 mL for 5 U per 0.1 mL where a lower concentration is preferred [4]. Rotate the vial slowly instead of shaking, keep the reconstituted solution refrigerated, and use it within 24 hours.

How long can Azzalure® be out of the fridge for?

Store unopened Azzalure® vials at 2°C to 8°C. The current SmPC permits a single excursion to a temperature not exceeding 25°C for up to 72 hours within the shelf life; this is a one-off allowance, not permission for routine room-temperature storage [4]. Reconstituted product should be refrigerated and used within 24 hours.

Where can practitioners find information on buying Azzalure®?

Licensed practitioners considering where to buy Azzalure® online can contact Doctor Medica representatives for guidance on eligibility, documentation, wholesale pricing, and shipping conditions. The process depends on jurisdiction, and Doctor Medica’s staff can point practitioners to the specifics relevant to their region.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations and Resources

[1] Rzany, B et al. “Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.” Journal of the European Academy of Dermatology and Venereology : JEADV vol. 24 Suppl 1 (2010): 1-14. doi:10.1111/j.1468-3083.2009.03475.x

[2] Scaglione, Francesco. “Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.” Toxins vol. 8,3 65. 4 Mar. 2016, doi:10.3390/toxins8030065

[3] Ascher, B et al. “International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)–Part I: Upper facial wrinkles.” Journal of the European Academy of Dermatology and Venereology : JEADV vol. 24,11 (2010): 1278-84. doi:10.1111/j.1468-3083.2010.03631.x

[4] Galderma (U.K.) Limited. “Azzalure, 125 Speywood Units, Powder for Solution for Injection: Summary of Product Characteristics (SmPC).” electronic Medicines Compendium (emc), Galderma (U.K.) Limited, https://www.medicines.org.uk/emc/product/6584/smpc.

[5] Nestor, Mark et al. “Onset and Duration of AbobotulinumtoxinA for Aesthetic Use in the Upper face: A Systematic Literature Review.” The Journal of clinical and aesthetic dermatology vol. 13,12 (2020): E56-E83.

Written by Doctor Medica’s Editorial team

The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.

Doctor Medica sources products exclusively through authorized distributors and established procurement channels. Products are verified as genuine, and supplied in the original packaging with their seal intact. Learn more about how we guarantee product authenticity, sourcing compliance, and traceable delivery to our clients.